Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline - Irene S. Yu, Francine Aubin, Rachel Goodwin, Jonathan M. Loree, Cheryl Mather, Brandon S. Sheffield, Stephanie Snow, Sharlene Gill,
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer | PPT
Metastatic Colon and Rectal Cancer Updates, ASCO 2022
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer - ScienceDirect
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences
Cancers | Free Full-Text | ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
Management of metastatic colorectal cancer | PPT
Metastatic Colon and Rectal Cancer Updates, ASCO 2022
Therapeutic landscape and future direction of metastatic colorectal cancer | Nature Reviews Gastroenterology & Hepatology
PARADIGM Trial: Panitumumab in RAS Wild-Type and Left-Sided Metastatic CRC
Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X
In Metastatic RAS Wild-Type Left-Sided Colorectal Cancer, Panitumumab Proves Superior to Bevacizumab - The ASCO Post
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper | Nature Reviews Clinical Oncology
Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? - ScienceDirect
PARADIGM Study Design & Clinical Data | Vectibix® (panitumumab)
Cancers | Free Full-Text | Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
PARADIGM - Slideset Download - Clinical Oncology 2022 | CCO
LBA1 Annual Meeting of the American Society of Clinical Oncology® 2022 | OncoTribune
Neoadjuvant immunotherapy in dMMR colon cancer
Cancers | Free Full-Text | A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer
Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy
PARADIGM ctDNA Analysis Shows Impact of Gene Alterations in Metastatic Colorectal Cancer
Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer | Semantic Scholar
PARADIGM ctDNA Analysis Shows Impact of Gene Alterations in Metastatic Colorectal Cancer
